Cancer Medical Cannabis Studies

A

• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)

B

• batten-disease (6)

• benefits (9)

• breast-cancer (7)

C

• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)

D

• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)

E

• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)

F

• fibromyalgia (2)

• fibrosis (1)

G

• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)

H

• health-care (1)

• hiv (7)

• huntingtons-disease (1)

I

• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)

K

• krabbe-disease (4)

L

• liver (2)

• lung-cancer (2)

• lupus (1)

M

• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)

N

• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)

P

• pain (29)

• pancreatitis (1)

• prostate-cancer (2)

S

• schizophrenia (2)

• skin (1)

• sports (3)

T

• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells (2006)

    Cannabidiol hydroxyquinone (HU-331) has a great potential to become an antiangiogenic and anticancer drug. This study demonstrated that HU-331 was able to significantly inhibit angiogenesis at very low concentrations, in addition to significantly decreasing the total area occupied by the vessels in the treated tumors. View study

  • A pilot clinical study of ?9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme (2006)

    Due to its ability to inhibit tumor growth in animals, THC and other cannabinoids have been suggested as antitumor drugs. This is the first clinical study to test the application of THC in human patients with recurrent glioblastoma multiforme. The results demonstrate the safety profile of THC and its action on tumor cells, which establishes the basis for future trials. View study

  • A selective review of medical cannabis in cancer pain managment. (2017)

    Insufficient management of chronic and neuropathic pain associated with cancer adversely affects the patient’s quality of life. The objective of this review was to present a selection of representative clinical studies, which evaluated the efficacy of cannabinoid-based treatments containing tetrahydrocannabinol (THC) and cannabidiol (CBD) to reduce pain associated with cancer. View study

  • Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors (2000)

    The results of this study indicate that cannabinoid receptors have a protective role against apoptosis induced by endocannabinoid anandamide (AEA) through vanilloid receptors. View study

  • Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells (2012)

    A study demonstrating that endogenous cannabinoid anandamide AEA inhibits the proliferation of cancer cells and induces cellular apoptosis, suggesting its therapeutic potential in the treatment of patients with human hepatocellular carcinoma. View study

  • Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy (2011)

    Findings that reveal the therapeutic potential of cannabinoids for the treatment of hepatocellular carcinoma, especially in advanced stages. View study

  • Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation (2000)

    THC (the main component of cannabis) induces apoptosis (cell death) of cancer cells in culture. Its intratumoral administration induced a considerable regression of malignant gliomas. View study

  • Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy (2007)

    Anandamide is potentially involved in the control of cancer growth directed both to the proliferation of tumor cells and to the angiogenic stimulation of the vasculature. View study

  • Anticancer mechanisms of cannabinoids (2016)

    There is a lot of evidence that shows how cannabinoids can reduce cancer tumors in animals. These findings already serve as the basis for the development of studies that analyze the therapeutic potential of cannabinoids to fight cancer. View study

  • Antitumorigenic Effects of Cannabinoids beyond Apoptosis (2009)

    Cannabinoids may likewise affect cancer cell angiogenesis, migration, invasion, adhesion, and metastasization. View study

  • Cannabidiol as potential anticancer drug (2012)

    There is emerging evidence to suggest that cannabidiol (CBD) is a potent inhibitor of cancer growth and spread. Its effectiveness is linked to its ability to target multiple cellular pathways that control tumorigenesis through the modulation of different intracellular signals depending on the type of cancer considered. View study

  • Cannabidiol Enhances the Inhibitory Effects of ?9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival (2010)

    Adding cannabidiol to ?9-THC may improve the effectiveness of ?9-THC in the treatment of glioblastoma in patients with cancer. When treating the cells with both compounds it was observed that these acted synergistically to inhibit cell proliferation. View study

  • Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma�Associated Herpesvirus Infected Endothelium (2012)

    Cannabidiol has properties that inhibit the expression of the herpesvirus receptor associated with Kaposi’s sarcoma, which leads to taking cannabidiol under clinical consideration for the treatment of Kaposi’s sarcoma. View study

  • Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1 (2012)

    Cannabinoids have the property of inhibiting the invasion of cancer cells by inducing the intercellular adhesion molecule-1 (ICAM-1), which in turn confers the induction of the tissue inhibitor of matrix metallo-proteinases-1 (TIMP-1). View study

  • Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma (2009)

    According to the results of this study, cannabinoid receptors have been shown to have antitumor properties in vitro and, for the first time, in vivo. This could represent a possible new treatment strategy that could improve the results in translocation-positive rhabdomyosarcoma. View study

  • Cannabinoid Receptor Agonist as an Alternative Drug in 5-Fluorouracil-resistant Gastric Cancer Cells (2013)

    The cannabinoid agonist WIN 55,212-2 is able to induce cytotoxicity in gastric cancer cells resistant to 5-FU. These results indicate that cannabinoids have potential to be used as therapy against gastric cancer resistant to 5-FU. View study

  • Cannabinoid receptor ligands as potential anticancer agents � high hopes for new therapies (2009)

    It is possible that cannabinoids have anticancer effects in the appropriate context, although their effects may not be significant enough for chemotherapy. Future studies will be able to demonstrate whether cannabinoids or cannabimimetic agents have the ability to reduce tumor growth in vivo synergistically with chemotherapeutic agents. View study

  • Cannabinoid Receptor-Mediated Apoptosis Induced by R()-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma (2006)

    The CB1 and CB2 receptors may have a great therapeutic potential for the treatment of mantle cell lymphoma. View study

  • Cannabinoid receptors as novel targets for the treatment of melanoma (2006)

    The activation of cannabinoid receptors CB1 and CB2 succeeded in reducing the growth, proliferation, angiogenesis and metastasis, and the increase of apoptosis, of melanomas in mice. This discovery may contribute to the design of new chemotherapeutic strategies for the treatment of melanoma. View study

  • Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis (2011)

    The cannabinoid receptors CB1 and CB2 have the potential to become therapeutic targets against non-small cell lung cancer. In this study it was demonstrated that the treatment of cell lines of this type of cancer with CB1 / CB2 and CB2-specific agonists Win55, 212-2 and JWH-015 significantly reduced both the growth factor-directed in vitro chemotaxis and chemoinvasion in these cells. View study

  • Cannabinoid-associated cell death mechanisms in tumor models (Review) (2012)

    Cannabinoids have been shown to possess certain anti-cancer qualities. A more in-depth exploration of the molecular mechanisms induced by cannabinoids on cancer cells could contribute to the development of safe and effective treatments in cancer therapy. View study

  • Cannabinoids and Cancer (2005)

    Cannabinoids have some anticancer properties, in addition to stimulating appetite, attenuate pain, inhibit nausea and vomiting. It is possible that cannabinoids can represent a new type of drugs with great utility in the fight against cancer, slowing its growth, inhibiting angiogenesis and metastatic spread of cancer cells. View study

  • Cannabinoids and cancer: pros and cons of an antitumour strategy (2006)

    Cannabinoids have the ability to selectively affect tumor cells more than their untransformed counterparts that may even be protected from cell death. These findings suggest that the cannabinoid system represents a promising target for cancer treatment. View study

  • Cannabinoids and ceramide: Two lipids acting hand-by-hand (2005)

    This study suggests that endocannabinoids constitute a new family of lipid signaling cues responsible for the regulation of the development and survival of neuronal cells, and provide a conceptual and mechanical basis for the effects of cannabinoids derived from marijuana. These findings provide a new conceptual view of how cannabinoids act and pose interesting physiological and therapeutic questions. However, more research is needed to determine the real impact of cannabinoids on brain development and the possible participation of ceramide in these events. View study